This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014
Conjugated equine estrogens plus medroxyprogesterone (MPA) did not increase the risk of developing atrial fibrillation, increased the risk of invasive breast cancer, and increased the incidence of deaths attributed to lung cancer compared to placebo in the Women's Health Initiative study. Women who used estrogen preparations containing MPA had a higher risk of venous thromboembolism in the Million Women Study. Another study found that the addition of MPA to oral estradiol in women with hot flashes increased the occurrence of supraventricular ectopic activity, which is associated with an increased risk of atrial fibrillation and stroke. One study found that micronized progesterone was effective for decreasing the frequency and severity of hot flashes and night sweats in healthy postmenopausal women when compared to placebo. There were no comparative studies of micronized progesterone versus MPA for the management of menopausal symptoms.
Subject indexing assigned by CRD
Administration, Oral; Humans; Medroxyprogesterone; Menopause; Progesterone
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published